DATA GRAPHICS | Data Byte
Orals faring worse than IV and subcutaneous products
By Gunjan Ohri, Data Content Analyst
Ocrevus revenues have been up and to the right ever since the drug launched in 2017, with 2024 no exception. Only one other newer entrant to the multiple sclerosis market appears to be taking off, with Kesimpta bringing in about $2.3 billion in the first nine months of the year, a 49% increase over the same period last year.
Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQB:RHHBY) is still the clear leader, bringing in $2 billion in 3Q24 sales alone. That number marked a new quarterly high for the CD20 mAb. Ocrevus’ sales of $5.7 billion in the first nine months of 2024 reflected 10% growth over the same period last year…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654285/ms-market-ocrevus-continues-to-grow-as-kesimpta-becomes-multi-blockbuster